CSL Behring has received approval from the US Food and Drug Administration (FDA) for a new 10g (50mL) vial size of Hizentra, an immune globulin subcutaneous (human) liquid drug. Hizentra, which is claimed to the first and only 20% ...
Tags: CSL Behring, Hizentra